Date post: | 22-Jan-2018 |
Category: |
Science |
Upload: | wei-garofolo |
View: | 37 times |
Download: | 0 times |
10 EUROPEAN SCIENTISTS WHO HAVE CO-FOUNDED BIOTECH
COMPANIES BY WEI GAROFOLO
Life has always been known to move s lower in Europe
-- especial ly in regards to academic, sc ient i f ic , and
technological advances. However, in spite of this
perceived lag, there are st i l l ample inspir ing
examples of thr iv ing research in the Li fe Sciences
f ie ld. Here are a l ist of scholars who have helped
shape European Biotech into what i t is today:
EMMANUELLE CHARPENTIERA co-discoverer of CRISPR (c lustered regular ly
interspaced short pal indromic repeats) , Emmanuel le
is current ly the director of the Max Planck Inst i tute
for Infect ion Biology, as wel l as the recipient of
several pr izes for her work -- which has a global
reach and impact .
However, Emmanuel le is a lso accredited for co-
founding ERS Genomics, which l icenses her
intel lectual property pertaining to CRISPR.
GREGOIRE COURTINECourt ine is both a scient ist and an entrepreneur.
Current ly , he is the lab director of the Center for
Neuroprosthet ics and Brain Mind Inst i tute at the
Swiss Federal Inst i tute of Technology (EPFL) , as wel l
as the CSO of G-Therapeutics , a company based both
in Switzerland and the Netherlands that is test ing
technologies to aid paralyzed pat ients walk again.
LUIGI NALDINI Naldini is credited with enhancing gene transfers by
introducing lent iv iral vectors, which are now a widely
used tool in both emerging therapeutics and
biomedical research.
Current ly , Naldini is the director of the San Raffaele
Telethon Inst i tute for Gene Therapy, as wel l as a
founder of Genenta, a company that is a part of the
scient i f ic board of US company Magenta
Therapeutics.
JENS NIELSEN With an astounding 400 publ ished academic papers
and several awards under his belt , Nielsen is now a
professor at Chaimers University of Technology in
Gothenburg, Sweden, as wel l as the CSO of Novo
Nordisk Foundation Center for Biosustainabi l i ty .
Nielsen is a lso known for founding several biotech
companies, including Fluxome Sciences, MycoTeQ,
MetaboGen, and Biopetrol ia .
MATHIAS UHLÉN Boast ing over 500 publ ished scient i f ic art ic les, Uhlén
now teaches courses in Microbiology and
Biotechnology at both the Royal Inst i tute of
Technology and the Technical University of Denmark.
Along with his extensive academic and scient i f ic
success, Uhlén is a lso credited with co-
founding Biotage, Aff ibody and At las Ant ibodies, as
wel l as s i t t ing on the boards of Novozymes and
SweTree Technologies.
PHILIPP BECKHOVE Current ly , Beckhove is the director of
the Regensburg Center of Intervent ional Immunology
at University of Regensburg, Germany.
Seeing as much of his t ime is dedicated to
researching translat ional medicine to aid in cancer
treatment development, i t is no surprise that his
entrepreneurial work is a long the same vein.
Beckhove founded and is now the Chairman of iOmx,
an immuno-oncology Biotech.
DUSKO EHRLICH Ehrl ich is current ly the a Research Director at the
French National Inst i tute for Agricultural Research. In
this posit ion, he has coordinated large projects such
as MetaHIT and MetaGenopol is , as wel l as pioneered
research in microbial genet ics and and the
microbiome.
He also co-founded Enterome in 2012, a Microbiome-
focused company now entering c l in ical tr ia ls .
MARK LOWDELL Lowdel l is the director of the Cel lular Therapy at the
Royal Free London NHS Foundation Trust , as wel l as
a professor of Cel l and Tissue Therapy at the
University Col lege London.
Addit ional ly , Lowdel l co-founded Achi l les
Therapeutics , which is current ly developing
personal ized therapies for metastat ic cancer.
GREG WINTER A pioneer in the development of humanizat ion
techniques and avid researcher of the early history
of monoclonal ant ibodies, Winter is lovingly referred
to as the "Grandfather of Biotechnology."
Given Winter 's extensive experience, i t should come
as no surprise that he launched one of the most
successful Biotechs ever: Cambridge Ant ibody
Technology, which was acquired by AstraZeneca for
over $700 mil l ion in 2006. Addit ional ly , he co-
founded Domantis , as wel l as Bicycle Therapeutics.
LUKE O’NEILL O'Nei l l is current ly a professor of Biochemistry at the
Tr inity Col lege Dubl in, where he is conduct ing
research on immunity and inf lammation.
In the past , he has identi f ied targets for drugs and
vaccines, f i led patents surrounding his research, and
co-founded Opsona Therapeutics. More recently ,
O'Nei l l co-founded Inf lazome, an early stage
pharmaceutical company developing targeted
therapies for inf lammatory diseases.
THANK YOU!